Education
About Us
Working with TipRanks
Follow Us
Interpace Diagnostics Group (DE:PF42)
BERLIN:PF42
Total Valuation
Interpace Diagnostics Group has a market cap or net worth of $3.49M. The enterprise value is €7.71M.
Market Cap$3.49M
Enterprise Value€7.71M
Share Statistics
Interpace Diagnostics Group has 4,423,093 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,423,093
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Interpace Diagnostics Group’s return on equity (ROE) is -3.02 and return on invested capital (ROIC) is 194.00%.
Return on Equity (ROE)-3.02
Return on Assets (ROA)0.45
Return on Invested Capital (ROIC)194.00%
Return on Capital Employed (ROCE)1.94
Revenue Per Employee422.76K
Profits Per Employee60.38K
Employee Count111
Asset Turnover3.17
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Interpace Diagnostics Group is 1.77. Interpace Diagnostics Group’s PEG ratio is 0.01.
PE Ratio1.77
PS Ratio0.00
PB Ratio-1.49
Price to Fair Value-5.34
Price to FCF0.88
Price to Operating Cash Flow0.71
PEG Ratio0.01
Income Statement
In the last 12 months, Interpace Diagnostics Group had revenue of 46.93M and earned 6.70M in profits. Earnings per share was 1.42.
Revenue46.93M
Gross Profit29.93M
Operating Income8.11M
Pretax Income6.95M
Net Income6.70M
EBITDA8.36M
Earnings Per Share (EPS)1.42
Cash Flow
In the last 12 months, operating cash flow was 4.65M and capital expenditures -876.00K, giving a free cash flow of 3.77M billion.
Operating Cash Flow4.65M
Free Cash Flow3.77M
Free Cash Flow per Share0.85
Dividends & Yields
Interpace Diagnostics Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change-39.49%
50-Day Moving Average0.98
200-Day Moving Average1.69
Relative Strength Index (RSI)48.72
Average Volume (3m)0.00
Important Dates
Interpace Diagnostics Group upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Interpace Diagnostics Group as a current ratio of 1.11, with Debt / Equity ratio of -264.14%
Current Ratio1.11
Quick Ratio1.11
Debt to Market Cap0.00
Net Debt to EBITDA0.53
Interest Coverage Ratio12.30
Taxes
In the past 12 months, Interpace Diagnostics Group has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate<0.01
Enterprise Valuation
Interpace Diagnostics Group EV to EBITDA ratio is 1.94, with an EV/FCF ratio of 4.31.
EV to Sales0.35
EV to EBITDA1.94
EV to Free Cash Flow4.31
EV to Operating Cash Flow3.50
Balance Sheet
Interpace Diagnostics Group has $1.46M in cash and marketable securities with $5.86M in debt, giving a net cash position of $4.39M billion.
Cash & Marketable Securities$1.46M
Total Debt$5.86M
Net Cash$4.39M
Net Cash Per Share$0.99
Tangible Book Value Per Share-$0.51
Margins
Gross margin is 63.77%, with operating margin of 17.28%, and net profit margin of 14.28%.
Gross Margin63.77%
Operating Margin17.28%
Pretax Margin14.81%
Net Profit Margin14.28%
EBITDA Margin17.81%
EBIT Margin16.21%
Analyst Forecast
The average price target for Interpace Diagnostics Group is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―